← Back to Clinical Trials
Recruiting NCT04705623

NCT04705623 Influence of Iyengar Yoga on the Bio-functional Age of Postmenopausal Women

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04705623
Status Recruiting
Phase
Sponsor Insel Gruppe AG, University Hospital Bern
Condition Postmenopausal
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2020-09-01
Primary Completion 2025-03-31

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Iyengar Yoga

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2020-09-01 with a primary completion date of 2025-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this Study is to find out if Iyengar-Yoga has a rejuvenating effect on women after menopause. The biofunctional status of the study participants will be assessed before and after a 12-week yoga program.

Eligibility Criteria

Inclusion Criteria: * Informed consent * Women after Menopause (defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40mlU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy) * Age over 18 years * At least 4 hot flushes per day (examined through the Menopause rating scale MRS-II) * No regular yoga practice for two years * German as native language * Willing to participate in 12 yoga classes as well as two 45 self practice sessions per week * Willing to assess biofunctional Status and give blood samples Exclusion Criteria: * Acute and/or serious disease in the past two years (e.g. Cancer, major surgery) * Autoimmune or chronic inflammatory disease (e.g. rheumatism, thyroid dysfunction) * Mental illness (e.g. Depression or anxiety disorder (HADS \>8)) * Acute or chronic back pain or herniated vertebral disc * Compulsion to participate in the trial * Attendance of less than 10 yoga lessons out of 12. * Hormone replacement therapy (HRT) * Smoking \> 20 Cigarettes per day or over 20 packyears * Consumption of \>30g alcohol per day (\>1 liter of beer or \>0.3 dl of wine) * Previous periodic participation in yoga classes within the last two years * Inability or contraindications to undergo the investigated intervention * Participants incapable of judgement or participants under tutelage Diabetes mellitus

Contact & Investigator

Central Contact

Petra o Stute, Prof. Dr. med

✉ petra.stute@insel.ch

📞 +41 31 63 2 13 33

Principal Investigator

Petra Stute, Prof. Dr. med

PRINCIPAL INVESTIGATOR

Universitätsklinik für Frauenheilkunde Bern

Frequently Asked Questions

Who can join the NCT04705623 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Postmenopausal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04705623 currently recruiting?

Yes, NCT04705623 is actively recruiting participants. Contact the research team at petra.stute@insel.ch for enrollment information.

Where is the NCT04705623 trial being conducted?

This trial is being conducted at Bern, Switzerland.

Who is sponsoring the NCT04705623 clinical trial?

NCT04705623 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Petra Stute, Prof. Dr. med at Universitätsklinik für Frauenheilkunde Bern. The trial plans to enroll 72 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology